Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + nucleos(t)ide analogues
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Subcutaneous (peginterferon Alfa-2a), Oral (nucleos(t)ide Analogues)
01
Overview
**peginterferon alfa-2a + nucleos(t)ide analogues** is a combination regimen used primarily for the treatment of chronic hepatitis B virus (HBV) infection. Peginterferon alfa-2a is a pegylated form of interferon alpha-2a, an immunomodulatory biologic that enhances the host immune response against HBV, while nucleos(t)ide analogues (such as entecavir, tenofovir, lamivudine, adefovir, or telbivudine) are small molecules that inhibit HBV DNA polymerase, effectively suppressing viral replication. The combination exploits complementary mechanisms: the immunostimulatory action of peginterferon and the potent antiviral effect of NAs, theoretically aiming to increase rates of hepatitis B surface antigen (HBsAg) loss and functional cure. While combination therapy has shown increased on-treatment suppression of HBV and decline in HBsAg, evidence does not consistently demonstrate significantly higher rates of long-term HBsAg seroconversion or functional cure over monotherapy.
- Brand names
- Pegasys
- Other names
- pegylated interferon alfa-2a + nucleos(t)ide analogs
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on peginterferon alfa-2a + nucleos(t)ide analogues.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + nucleos(t)ide analogues.